中国药业2017，Vol.26Issue(23)：64-66,3.DOI:10.3969/j.issn.1006-4931.2017.23.022
不同剂量沙美特罗替卡松辅助治疗支气管哮喘临床评价
Clinical Evaluation of Different Doses of Salmeterol and Fluticasone in Adjuvant Treatment of Bronchial Asthma
吕媛媛 1刘洋 1杨军1
作者信息
- 1. 首都医科大学宣武医院,北京 100053
- 折叠
摘要
Abstract
Objective To observe the clinical efficacy and safety of different doses of salmeterol and fluticasone in adjuvant treatment of bronchial asthma. Methods Totally 92 patients with bronchial asthma admitted to our hospital in the same period were selected and randomly divided into the low dose group and the high dose group. On the basis of same basic treatment, the low dose group and the high dose group were treated with 50 μg/250 μg,50 μg/500 μg Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhala-tion, respectively. Results The remission time of the clinical symptoms in the high dose group was shorter than that in the low dose group ( P < 0. 05 ) . After 10 d of treatment, the lung function index and asthma symptom score of the high dose group were better than those of the low dose group ( P < 0. 05 ) . After 30, 90 d of treatment, there was no significant difference in lung function index and asthma symptom score between the two groups ( P > 0. 05 ) . No serious adverse reactions occurred in the two groups during the treatment. Conclusion In the attack stage of bronchial asthma, high dose of salmeterol and fluticasone should be the first choice for treatment, which can control the clinical symptoms of the patients. In the stable stage of bronchial asthma, low dose of salmeterol and fluticasone should be the first choice for treatment, which can well control the symptoms of asthma, and it is safe and reliable.关键词
沙美特罗替卡松/剂量/支气管哮喘/临床疗效/安全性Key words
salmeterol and fluticasone/dose/bronchial asthma/clinical effect/safety分类
医药卫生引用本文复制引用
吕媛媛,刘洋,杨军..不同剂量沙美特罗替卡松辅助治疗支气管哮喘临床评价[J].中国药业,2017,26(23):64-66,3.
